ChEMBL

Myelofibrosis is a disorder of the bone marrow, in which the marrow is replaced by scar (fibrous) tissue. Scarring of the bone marrow reduces its ability to blood cells, and can lead to anemia, bleeding problems, and a higher risk of infections due to reduced white blood cells. It is also associated with engorgement of organs suchs as the spleen and liver. Primary myelofibrosis may develop to secondary myelofibrosis - including leukemia and lymphoma. Myelofibrosis is associated with dysregulated Janus kinases JAK1 and JAK2, and some with a somatic mutation in JAK2 (JAK2V617F) (OMIM). JAK signaling involves recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors, activation and subsequent localization of STATs to the nucleus leading to modulation of gene expression. Oral administration of ruxolitinib prevented splenomegaly, preferentially decreased JAK2V617F mutant cells in the spleen and decreased circulating inflammatory cytokines.

JAK1 (Uniprot:P23458) and JAK2 (Uniprot:O60674) are tyrosine protein kinases and members of the Janus kinase subfamily, where all members of the family contain two tandem protein kinase domains (PFAM:PF00069), one of which is catalytically active and one believed to be inactive. JAK1 and JAK2 are 43% identical by sequence and both have the 3D structure of their kinase domain determined (see e.g. PDBe:3EYH and PDBe:3Q32 for JAK1 and JAK2 respectively). Ruxolitinib is the first approved targeted JAK inhibitor, with several others in mid to late-stage clinical development (including CYT-387, GLPG-0634, INCB-28050, ONX-0803, NS-018, pacritinib (SB-1518), AZD-1480, BMS-911543, LS-104, XL-019, TG-101348, tofacitinib (CP-690550), VX-509, R-348, WHI-P131 and oclacitinib (PF-03394197) (veterinary applications)) - note these show a broad range of selectivity against the three known JAK subtypes.
Ruxolitinib (IUPAC: (R)-3-(4-(7H-pyrrolo[2,3­ d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate; (Standard InCHI key: HFNKQEVNSGCOJV-OAHLLOKOSA-N) has a molecular weight of 404.36, an AlogP of 2.88 and complies with all components of Lipinski's rule of 5.

Ruxolitinib is administered orally as the phosphate salt as tablets and dosed according to platelet count (hence the large range of dosage forms). Each tablet contains ruxolitinib phosphate equivalent to 5 mg, 10 mg, 15 mg, 20 mg and 25 mg of ruxolitinib free base. The Tmax for Ruxolitinib is 1-2 hours post dosing, with exposure (Cmax and AUC) linear over a dose range of 5mg to 200mg. Oral absorption is in excess of 95%. The volume of distribution is 53-65 L, with plasma protein binding in excess of 97%. Ruxolitinib is predominantly metabolized by CYP3A4, with the two primary metabolites displaying weaker, but still significant pharmacological activity against their specific targets. Administration of ruxolitinib with ketoconazole, a potent CYP3A4 inhibitor, prolongs the half life of ruxolitinib from 3.7 to 6.0 hours, increases the C_max to 33% and the AUC to 91%. The change in the pharmacodynamic marker, pSTAT3 inhibition, was consistent with the corresponding ruxolitinib AUC following concurrent administration with ketoconazole.

The license holder for Jakafi is Incyte, and the full prescribing information can be found here.